Alkem Laboratories Signs Licensing Deal with Sonnet BioTherapeutics
Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings.
SON-080 | 10/10/2024 | By Aishwarya | 116
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy